drugset / Trial / NCT01278810
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients
Phase 1
Unknown
30 enrolled
Chinese Academy of Medical Sciences
Beijing Shenogen Biomedical Co., Ltd · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To assess safety, tolerance and PK profile of different doses(50mg,100mg,200mg,300mg, 400mg, 500mg,QD)of Icaritin in advanced breast cancer Patients in China
Timeline
- Start
- 2010-11
- Primary completion
- 2011-11
- Completion
- 2011-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Icaritin | Small molecule | 50 mg | Oral |
| Subject | Icaritin | Small molecule | 100 mg | Oral |
| Subject | Icaritin | Small molecule | 200 mg | Oral |
| Subject | Icaritin | Small molecule | 300 mg | Oral |
| Subject | Icaritin | Small molecule | 400 mg | Oral |
| Subject | Icaritin | Small molecule | 500 mg | Oral |